5 Biotech Stocks in Focus; CTIC, DSCO, STEM, AEZS, BPAX

Cell Therapeutics Inc. ( NASDAQ: CTIC ) is a Seattle, Washington-based biotechnology company, engaged in the development, acquisition and commercialization of treatments for cancer. The company is focusing on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Cell Therapeutics, recently, announced that it filed an appeal on FDA decision on New Drug Application for pixantrone to treat relapsed/refractory aggressive non-hodgkin's lymphoma. The penny stock of Cell Therapeutics has a 52-week range of $0.12-$1.40. Year-to-date, the stock is down 67.82%. Discovery Laboratories Inc. ( NASDAQ: DSCO ) is a Warrington, Pennsylvania-based biotechnology company, engaged in the development of surfactant therapies to treat respiratory disorders and diseases. Last week, Discovery announced that NIH awarded it Fast Track SBOR grant to support development of aerosolized KL4 surfactant. The penny stock of Discovery Laboratories has a 52-week range of $0.17-$0.84. Year-to-date, the stock is down 42.72%. StemCells Inc. ( NASDAQ: STEM ) is a Palo Alto, California-based biotechnology company, engaged in the research, development and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. Earlier this month, StemCells received authorization to conduct the world's first ever neural stem cell trial in spinal cord injury. The penny stock of StemCells has a 52-week range of $0.75-$1.58. Year-to-date, the stock is down 10.34%. AEterna Zentaris Inc. ( NASDAQ: AEZS ) is a Canada-based drug development company, specializing in oncology and endocrine therapy. Last week, AEterna Zentaris announced that it received agreement from FDA on SPA for Solorel® to complete registration study for diagnosis of adult growth hormone deficiency. The penny stock of AEterna Zentaris has a 52-week range of $0.78-$2.19. Year-to-date, it is up 113.15%. BioSante Pharmaceuticals Inc. ( NASDAQ: BPAX ) is a Lincolnshire, Illinois-based specialty pharmaceutical company. The company focuses on the development of products for female sexual health, menopause, contraception and male hypogonadism. On Monday, BioSante announced that it will raise $18 million in registered direct offering. The penny stock of BioSante has a 52-week range of $1.29-$2.50. Year-to-date, the stock is up 14.48%. This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in these stocks. We reserve the right to buy or sell CTIC, DSCO, STEM, AEZS and BPAX at any time after this post.
Negocioenlinea
tdp2664Penny Stock Live